Johnson & Johnson vs. Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc. Common Stock (RNA) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| JNJ | RNA | |
|---|---|---|
| Market Cap | $663.28 billion | $194.15 million |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | — |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| JNJ | RNA | |
|---|---|---|
| P/E Ratio | 31.22 | — |
| Price / Book | 7.81 | 0.90 |
| Price / Sales | 6.77 | — |
RNA leads on 1 of 1 valuation factors.
Profitability
| JNJ | RNA | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | — |
JNJ and RNA split the profitability factors evenly.
Dividend
| JNJ | RNA | |
|---|---|---|
| Dividend Yield | 1.99% | — |
| Payout Ratio | 62.18 | — |
JNJ and RNA split the dividend factors evenly.
Risk & Sentiment
| JNJ | RNA | |
|---|---|---|
| Short Interest | 0.67% | 0.00% |
RNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, RNA overview, RNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.